Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions

被引:9
|
作者
Economopoulou, Panagiota [1 ]
Pantazopoulos, Anastasios [1 ]
Spathis, Aris [2 ]
Kotsantis, Ioannis [1 ]
Kyriazoglou, Anastasios [1 ]
Kavourakis, George [1 ]
Zakopoulou, Roubini [1 ]
Chatzidakis, Ioannis [1 ]
Anastasiou, Maria [1 ]
Prevezanou, Maria [1 ]
Resteghini, Carlo [3 ]
Licitra, Lisa [3 ,4 ]
Bergamini, Cristiana [3 ]
Colombo, Elena [3 ]
Caspani, Francesca [3 ]
Denaro, Nerina [5 ]
Vecchio, Stefania [6 ]
Bonomo, Pierluigi [7 ]
Cossu Rocca, Maria [8 ]
Bertolini, Federica [9 ]
Ferrari, Daris [10 ]
Psyrri, Amanda [1 ]
Bossi, Paolo [11 ]
机构
[1] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Internal Med 2, Sect Med Oncol, Athens 12462, Greece
[2] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Dept Pathol 2, Athens 12462, Greece
[3] Fdn IRCCS Ist Nazl Tumori, Head & Neck Med Oncol Unit, Via Venezian 1, I-20133 Milan, Italy
[4] Univ Milan, Dept Oncol & Hematooncol, I-20122 Milan, Italy
[5] Med Oncol Santa Croce & Carle Gen Hosp Cuneo, I-12100 Cuneo, Italy
[6] IRCCS Osped Policlin San Martino, I-16132 Genoa, Italy
[7] Azienda Osped Univ Careggi, Radiat Oncol, I-50134 Florence, Italy
[8] European Inst Oncol IRCCS, Dept Med Oncol Urogenital & Head & Neck Tumors Me, IEO, I-20141 Milan, Italy
[9] Univ Hosp Modena, Dept Hematol & Oncol, Med Oncol Unit, I-41125 Modena, Italy
[10] San Paolo Hosp, Med Oncol Unit, I-20142 Milan, Italy
[11] Univ Brescia, ASST Spedali Civili, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Med Oncol, I-25123 Brescia, Italy
关键词
immunotherapy; nasopharyngeal cancer; EBV DNA; nonendemic region; ANTITUMOR-ACTIVITY; PHASE-II; RECURRENT; CHEMOTHERAPY; MULTICENTER; PEMBROLIZUMAB; CAMRELIZUMAB; BIOMARKERS; CANCER; SAFETY;
D O I
10.3390/cells11010032
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited. Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8 centers in Italy. Between 2016 and 2021, 46 patients who were treated with at least one cycle of immune checkpoint inhibitors (ICI) were identified. Herein, we present our results and a review of the literature. Results: assessment of response was available in 42 patients. Overall, 11 patients responded to immunotherapy (Overall Response Rate-ORR 26.2%). Three patients had complete response (CR), and 8 patients had partial response (PR). Disease control rate (DCR) was 61.9%. Median Progression Free Survival (PFS) was 5.6 months and median Overall Survival (OS) was 19.1 months. Responders to ICI improved PFS and OS as compared to that of nonresponders. A lower probability of responding to ICI was shown in patients with more than three metastatic sites (p = 0.073), metastatic disease at initial diagnosis, (p = 0.039) or EBV DNA positive before ICI initiation, (p = 0.074). Decline in EBV DNA levels was found to be statistically significant associated with best response to ICI (p = 0.049). Safety was manageable. Conclusions: among 46 patients with R/M NPC treated with immunotherapy in two nonendemic regions, ORR was 26.2% and durable responses were observed. Low disease burden could serve as a biomarker for response to ICI.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Patient Characteristics and Treatment Outcomes of Nasopharyngeal Carcinoma in Nonendemic Regions
    Alsavaf, Mohammad Bilal
    Marquardt, Matthew
    Abouammo, Moataz D.
    Xu, Menglin
    Elguindy, Ahmed
    Grecula, John
    Baliga, Sujith
    Konieczkowski, David
    Gogineni, Emile
    Bhateja, Priyanka
    Rocco, James W.
    Old, Matthew O.
    Blakaj, Dukagjin M.
    Carrau, Ricardo L.
    Vankoevering, Kyle K.
    Bonomi, Marcelo
    JAMA NETWORK OPEN, 2025, 8 (03)
  • [2] Outcomes in nasopharyngeal carcinoma: Results from a nonendemic cohort
    Laskar, S. G.
    Gurram, L.
    Gupta, T.
    Budrukkar, A.
    Murthy, V
    Agarwal, J. P.
    INDIAN JOURNAL OF CANCER, 2016, 53 (04) : 493 - 498
  • [3] Loco-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma with chemotherapy and immunotherapy: A real-world retrospective study from two cancer centers
    Ma, Li
    Lan, Fengming
    Chen, Peng
    Lei, Ling
    Zou, Teng
    Fu, Fangmeng
    Wu, Runye
    Jin, Jing
    Zhang, Jianghu
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (08): : 1932 - 1937
  • [4] Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan
    Manako, Tomomi
    Yasumatsu, Ryuji
    Nakano, Takafumi
    Matsuo, Mioko
    Takeuchi, Toranishin
    Taura, Masahiko
    Tamae, Akihiro
    Yamauchi, Moriyasu
    Masuda, Muneyuki
    Taguchi, Kenichi
    Nakagawa, Takashi
    IN VIVO, 2023, 37 (02): : 747 - 755
  • [5] Nonendemic HPV-Positive Nasopharyngeal Carcinoma: Association With Poor Prognosis
    Stenmark, Matthew H.
    McHugh, Jonathan B.
    Schipper, Matthew
    Walline, Heather M.
    Komarck, Christine
    Feng, Felix Y.
    Worden, Francis P.
    Wolf, Gregory T.
    Chepeha, Douglas B.
    Prince, Mark E.
    Bradford, Carol R.
    Mukherji, Suresh K.
    Eisbruch, Avraham
    Carey, Thomas E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (03): : 580 - 588
  • [6] Real-world data of immunotherapy from China in recurrent or metastatic head and neck squamous cell carcinoma
    Zhang, Ximei
    Wang, Peiguo
    Chai, Yanlan
    Zhou, Xuan
    Li, Ping
    Wang, Xudong
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2024, 45 (01)
  • [7] Real-World Use of Immunotherapy for Hepatocellular Carcinoma
    Sara, Amir
    Ruff, Samantha M.
    Noonan, Anne M.
    Pawlik, Timothy M.
    PRAGMATIC AND OBSERVATIONAL RESEARCH, 2023, 14 : 63 - 74
  • [8] Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances
    Rallis, Kathrine S.
    Makrakis, Dimitrios
    Ziogas, Ioannis A.
    Tsoulfas, Georgios
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2022, 13 (06): : 448 - 472
  • [9] Treatment of nasopharyngeal carcinoma in the modern era: Analysis of outcomes and toxicity from a single center in a nonendemic area
    Yee, D
    Hanson, J
    Lau, H
    Siever, J
    Gluck, S
    CANCER JOURNAL, 2006, 12 (02) : 147 - 154
  • [10] Real-world efficacy, safety data and predictive clinical parameters for treatment outcomes in advanced soft tissue sarcoma treated with combined immunotherapy and antiangiogenic therapy
    Li, Shaoli
    Sun, Qunan
    Bai, Rui
    Wang, Youping
    Wang, Hui
    Chen, Haifeng
    Dong, Ying
    BMC CANCER, 2024, 24 (01)